{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:46:52Z","timestamp":1793033212198,"version":"4.5.0"},"reference-count":32,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Excellent Discipline Leader Cultivation Program of Shanghai","award":["GWV-10.2-XD09"],"award-info":[{"award-number":["GWV-10.2-XD09"]}]},{"name":"National Key R<D Program","award":["2021YFC2702100"],"award-info":[{"award-number":["2021YFC2702100"]}]},{"name":"Shanghai Health Commission Research Project","award":["201840199"],"award-info":[{"award-number":["201840199"]}]},{"name":"Shanghai Health Commission Research Project","award":["20214Y0427"],"award-info":[{"award-number":["20214Y0427"]}]},{"name":"The Shanghai Science and Technology Commission Research Project","award":["18ZR1435700"],"award-info":[{"award-number":["18ZR1435700"]}]},{"name":"Three-year Action Program of Public Health","award":["GWV-9.1"],"award-info":[{"award-number":["GWV-9.1"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2024,7,21]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To assess the effect of weekly 1% atropine use on children\u2019s myopia progression and whether the effect is sustainable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical records of myopic children aged 3\u201315 years receiving weekly 1% atropine for more than 1 year were retrospectively reviewed. Axial length (AL) and spherical equivalent refraction (SER) at every visit were collected. The changes in AL or SER over time were analysed using generalised estimating equation. The related factors of myopic progression were performed by multiple linear regression. The performance of short-term AL change to predict atropine-poor responders (AL change &gt;0.2\u2009mm\/year) was assessed using receiver operating characteristic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 694 participants with a mean age of 8.83 years were included. The participants with follow-up time reached 1, 2, 3 and 4 years were 256 (36.9%), 250 (36.0%), 143 (20.6%) and 45 (6.5%) separately. The cumulative change in AL was 0.05\u2009mm, 0.24\u2009mm, 0.47\u2009mm, 0.56\u2009mm separately for 1-year, 2-year, 3-year and 4-\u2009year treatment. Approximate 0.20\u2009mm elongation per year was observed since the second-year of the treatment. Older age and lower initial myopic refraction were independently associated with less myopic progression. A decrease in AL of more than 0.04\u2009mm during the initial 2 months could serve as an indicator for identifying fast progressors (AL change &gt;0.2\u2009mm\/year) over a 2-year period, with sensitivity and specificity rates of 0.78 and 0.73, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Weekly 1% atropine may be a potentially effective treatment with longer lasting effects for children with myopia control especially in those with older age and lower myopia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2023-324615","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T13:21:53Z","timestamp":1723209713000},"page":"264-272","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of weekly dose of 1% atropine for myopia control in Chinese children"],"prefix":"10.1136","volume":"109","author":[{"given":"Linlin","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2279-9514","authenticated-orcid":false,"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4031-7040","authenticated-orcid":false,"given":"Jinliuxing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sichen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8938-1879","authenticated-orcid":false,"given":"Xiangui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7196-9340","authenticated-orcid":false,"given":"Mengjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"2025040422453030000_109.2.264.1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/IAE.0000000000002590","article-title":"Prevalence and time trends of myopia in children and adolescents in China: a systemic review and meta-analysis","volume":"40","author":"Dong","year":"2020","journal-title":"Retina"},{"key":"2025040422453030000_109.2.264.2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/iovs.62.5.2","article-title":"IMI impact of myopia","volume":"62","author":"Sankaridurg","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025040422453030000_109.2.264.3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.3451"},{"key":"2025040422453030000_109.2.264.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.11.010"},{"key":"2025040422453030000_109.2.264.5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/opo.12052","article-title":"How does atropine exert its anti-myopia effects?","volume":"33","author":"McBrien","year":"2013","journal-title":"Ophthalm Physiol Opt"},{"key":"2025040422453030000_109.2.264.6","first-page":"180","article-title":"Comparison of the effect of atropine and cyclopentolate on myopia","volume":"21","author":"Yen","year":"1989","journal-title":"Ann Ophthalmol"},{"key":"2025040422453030000_109.2.264.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.05.062"},{"key":"2025040422453030000_109.2.264.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.10.020"},{"key":"2025040422453030000_109.2.264.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.07.004"},{"key":"2025040422453030000_109.2.264.10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"key":"2025040422453030000_109.2.264.11","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s10792-020-01356-x","article-title":"Part-time use of 1% atropine eye drops for prevention of myopia progression in children","volume":"40","author":"Foo","year":"2020","journal-title":"Int Ophthalmol"},{"key":"2025040422453030000_109.2.264.12","first-page":"1","article-title":"Expert consensus on the application of axial length in myopia prevention and control management (2023)","volume":"42","year":"2024","journal-title":"Chin J Exp Ophthalmol"},{"key":"2025040422453030000_109.2.264.13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-14-141"},{"key":"2025040422453030000_109.2.264.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.029"},{"key":"2025040422453030000_109.2.264.15","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"2025040422453030000_109.2.264.16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.7150\/ijms.39365","article-title":"Efficacy and safety of 1% atropine on retardation of moderate myopia progression in Chinese school children","volume":"17","author":"Zhu","year":"2020","journal-title":"Int J Med Sci"},{"key":"2025040422453030000_109.2.264.17","first-page":"1859","article-title":"Combination with different anticholinergic eyedrops for the treatment of children myopia","volume":"99","author":"Han","year":"2019","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2025040422453030000_109.2.264.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69710-8"},{"key":"2025040422453030000_109.2.264.19","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12722"},{"key":"2025040422453030000_109.2.264.20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"key":"2025040422453030000_109.2.264.21","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41433-020-1122-7","article-title":"A 3-year follow-up study of atropine treatment for progressive myopia in Europeans","volume":"34","author":"Polling","year":"2020","journal-title":"Eye (Lond)"},{"key":"2025040422453030000_109.2.264.22","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s40123-022-00572-1","article-title":"Efficacy and safety of consecutive use of 1% and 0.01% atropine for myopia control in Chinese children: the atropine for children and adolescent myopia progression study","volume":"11","author":"Ye","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"2025040422453030000_109.2.264.23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2021.12.014","article-title":"The association of choroidal thickening by atropine with treatment effects for myopia: two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study","volume":"237","author":"Yam","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"2025040422453030000_109.2.264.24","article-title":"Effects of atropine treatment on choroidal thickness in myopic children","volume":"61","author":"Ye","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025040422453030000_109.2.264.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2010.08.021"},{"key":"2025040422453030000_109.2.264.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2009.12.002"},{"key":"2025040422453030000_109.2.264.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-016-0002-7"},{"key":"2025040422453030000_109.2.264.28","unstructured":"ZEISS . IOLMaster technical specifications. 2023 Available: https:\/\/www.zeiss.com\/meditec\/en\/products\/optical-biometers\/iolmaster-700-us\/specifications-us.html"},{"key":"2025040422453030000_109.2.264.29","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-7364"},{"key":"2025040422453030000_109.2.264.30","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-1833"},{"key":"2025040422453030000_109.2.264.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.12.036"},{"key":"2025040422453030000_109.2.264.32","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-10565"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2023-324615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T04:40:46Z","timestamp":1744000846000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2023-324615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bjo-2023-324615"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2023-324615","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]}}}